At 48 weeks, adults with obesity or overweight and type 2 diabetes taking EloraTZP lost an average of 54.1 pounds, and up to 77% reached normal blood sugar levels. That combination, weight and glycemic control together, is what Lilly is bringing to ObesityWeek 2026 this week in Washington, and it makes the EloraTZP Phase 2 results arguably the most watched dataset in the company’s conference slate.
EloraTZP pairs eloralintide with tirzepatide, the dual GIP/GLP-1 agonist already approved as Zepbound. At 48 weeks, up to 60% of participants no longer met BMI criteria for obesity, and A1C dropped by an average of 2.9 percentage points. Those are Phase 2 numbers with all the caveats that implies, but they set a high bar for what Phase 3 would need to replicate. Retatrutide, Lilly’s triple agonist targeting GIP, GLP-1, and glucagon receptors, adds a different dimension: in TRIUMPH-1, it cut breathing disruptions during sleep by up to an average of 36.1 events per hour over 80 weeks in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight, and separately reduced knee osteoarthritis pain scores by up to an average of 73.1% on the WOMAC pain subscale in adults with knee osteoarthritis pain and obesity or overweight. In TRIUMPH-4, the osteoarthritis pain reduction reached up to an average of 75.8% at 68 weeks. These are the kinds of downstream disease outcomes that position retatrutide beyond weight-focused labeling, though it remains investigational.
The adolescent data for approved Zepbound fills a gap regulators and pediatric endocrinologists have been watching: in SURMOUNT-ADOLESCENTS, tirzepatide reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 years with obesity, with more than half no longer meeting obesity BMI criteria at 72 weeks. On the oral side, real-world survey data from the FOUNDERS study showed 96 to 98% of Foundayo users found the once-daily pill simple and easy to use regardless of timing or food intake, a practical point that matters for adherence in a market where injectable dosing schedules drive discontinuation. Eloralintide exit interviews added something less common in obesity trial reporting: 74% of participants reported fewer food cravings at 48 weeks, and 41% of those who drank alcohol at baseline reported drinking less.
The number to track from this conference is retatrutide’s AHI reduction in TRIUMPH-2, the cohort with both sleep apnea and type 2 diabetes, where the up-to-48.1% reduction seen in TRIUMPH-2 versus the up-to-60.6% reduction in TRIUMPH-1. How Lilly frames that gap in the oral session will shape how clinicians and regulators think about the drug’s benefit profile in its most complicated patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
